ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.

Ms. Josephine Baum Jorgensen

Chief Financial Officer

David Stig Poulsen

Head of Marketing

Dr. Jesper  Eugen-Olsen

Co-Founder & Chief Scientific Officer

Mr. Jakob  Knudsen

Chief Executive Officer

Ms. May Britt Dyvelkov

Vice President of Accounting

Mr. Thomas  Krarup

Vice President of Global Sales & Marketing

ViroGates A/S

ViroGates A/S Struktura zarządzania

Informacje o kierownictwie